Collegium Pharmaceutical, Inc. (COLL) News

Collegium Pharmaceutical, Inc. (COLL): $40.91

0.98 (+2.45%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

A

Add COLL to Watchlist
Sign Up

Filter COLL News Items

COLL News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

COLL News Highlights

  • For COLL, its 30 day story count is now at 3.
  • Over the past 9 days, the trend for COLL's stories per day has been choppy and unclear. It has oscillated between 1 and 1.

Latest COLL News From Around the Web

Below are the latest news stories about COLLEGIUM PHARMACEUTICAL INC that investors may wish to consider to help them evaluate COLL as an investment opportunity.

Collegium Pharmaceutical Inc CEO Joseph Ciaffoni Sells Company Shares

On December 21, 2023, Joseph Ciaffoni, President and CEO of Collegium Pharmaceutical Inc (NASDAQ:COLL), executed a sale of 4,357 shares of the company.

Yahoo | December 23, 2023

Collegium Pharmaceutical Inc CEO Joseph Ciaffoni Sells 68,768 Shares

Joseph Ciaffoni, the President and CEO of Collegium Pharmaceutical Inc (NASDAQ:COLL), sold 68,768 shares of the company on December 20, 2023, according to a recent SEC filing.

Yahoo | December 21, 2023

Collegium Pharmaceutical (NASDAQ:COLL) ascends 8.3% this week, taking five-year gains to 77%

The main point of investing for the long term is to make money. Better yet, you'd like to see the share price move up...

Yahoo | December 14, 2023

Insider Sell: EVP and General Counsel Shirley Kuhlmann Sells 25,600 Shares of Collegium ...

Shirley Kuhlmann, the Executive Vice President and General Counsel of Collegium Pharmaceutical Inc, has recently sold 25,600 shares of the company's stock.

Yahoo | November 30, 2023

Appeals Court Upholds PTAB’s Finding of Invalidity of Purdue’s 961 Patent

STOUGHTON, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that the U.S. Court of Appeals for the Federal Circuit has upheld the judgment of the Patent Trial and Appeal Board (PTAB) in its final decision that Purdue’s ‘961 patent, which Purdue has claimed is infringed by Xtampza® ER, is invalid. The Federal Circuit’s decision affirming the invalidity of Purdue’s ‘961 patent confirms b

Yahoo | November 27, 2023

12 Cheap NASDAQ Stocks To Buy

In this piece, we will take a look at the 12 cheap NASDAQ stocks to buy. To skip our overview of one of the world’s largest stock exchanges and some recent financial news, read 5 Cheap NASDAQ Stocks To Buy. Stocks markets have been taking a hammering over the past couple of years amid a […]

Yahoo | November 14, 2023

Collegium Announces $25 Million Accelerated Share Repurchase Program

STOUGHTON, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it has entered into an Accelerated Share Repurchase ("ASR") agreement with Jefferies LLC to repurchase $25 million of the Company’s common stock. Collegium will execute the ASR as part of the $100 million share repurchase program authorized

Yahoo | November 9, 2023

Should You Be Worried About Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) 5.0% Return On Equity?

One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...

Yahoo | November 9, 2023

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q3 2023 Earnings Call Transcript

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q3 2023 Earnings Call Transcript November 7, 2023 Collegium Pharmaceutical, Inc. misses on earnings expectations. Reported EPS is $0.53 EPS, expectations were $1.24. Operator: Greetings, and welcome to Collegium Pharmaceuticals Third Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow […]

Yahoo | November 8, 2023

Here's What Key Metrics Tell Us About Collegium Pharmaceutical (COLL) Q3 Earnings

While the top- and bottom-line numbers for Collegium Pharmaceutical (COLL) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Yahoo | November 8, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!